Articles
By decreasing the cost of drug discovery, a novel invention could potentially allow for increased access to high-quality healthcare and benefit cancer patients receiving personalized chemotherapy treatments. The details were published in a recent issue of the journal Biomaterials.
Treating actinic keratosis, a skin condition that is the most common precursor to sun-related squamous cell carcinoma, can require months with current available therapies. Now, a new topical gel is available by prescription that significantly decreases the amount of treatment time, according to a multicenter phase 3 trial led by researchers at Mount Sinai School of Medicine. The newly approved gel, ingenol mebutate, is applied to the skin for just a few days, making treatment faster and even more effective.
Since 1971, the number of cancer survivors in the US has tripled. However, with the achievements in patient survival have come second malignancies and cardiovascular disease among survivors, according to a report by a national scientific committee convened by the National Council on Radiation Protection and Measurements.
The National Comprehensive Cancer Network® (NCCN®) has issued new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adolescent and Young Adult (AYA) Oncology. AYA patients are individuals 15 to 39 years of age at initial cancer diagnosis. The critical issues that AYA patients with cancer and their caregivers encounter at diagnosis, during treatment, and after therapy are addressed in the guidelines.
As breakthroughs in personalized cancer treatment continue, delivering the specialized therapies in the most cost-effective manner has grown increasingly important. In a paper published in the British Journal of Cancer, University of Colorado School of Medicine researchers have identified new ways for allowing more patients to benefit from this revolution in cancer care.
A new approach involving billions of clones of patients’ own tumor-fighting cells in combination with a specific form of chemotherapy is showing promise in the fight against advanced melanoma. The results of the Fred Hutchinson Cancer Research Center study are published in the March 5 Early Edition of the Proceedings of the National Academy of Sciences.
A landmark study published in the New England Journal of Medicine may help explain why identifying biomarkers for personalized cancer treatments through single biopsies have not been more successful.
To better inform physicians and patients and increase their understanding of the benefits of colorectal cancer screening, the American College of Physicians (ACP) has issued a new guidance statement for colorectal cancer screening. The guidance statement appears in the March 6 issue of Annals of Internal Medicine.
Researchers have discovered a potential treatment option for clinically advanced metastatic tumors. The novel treatment involves combining 2 drugs previously administered to a patient that are no longer effective. Together, the 2 drugs boost one another’s efficacy while at the same time breaking down the patient’s resistance to each of the drugs individually. The treatment study, lead by the Vall d’Hebron Institute of Oncology (VHIO), was recently published in the Journal of Clinical Oncology.
When a patient is facing a serious condition, such as cancer, diagnosing depression becomes complicated. The psychological and somatic symptoms medical professionals are trained to look for are often attributed to the primary medical condition, which means depression may go undiagnosed in cancer patients. In fact, it is thought that more than half of depressions are overlooked in medical settings.